Patents by Inventor Walter A. Blattler

Walter A. Blattler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20130108620
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 2, 2013
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Gail Colbern Schwall
  • Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
    Patent number: 8337856
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: December 25, 2012
    Assignee: Immunogen, Inc.
    Inventors: Walter Blättler, Ravi V. J. Chari
  • METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
    Publication number: 20120226025
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: IMMUNOGEN, INC.
    Inventors: Ravi V.J. CHARI, Wayne WIDDISON, Rita M. STEEVES, Walter A. BLATTLER
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 8198417
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 12, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 8163888
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 24, 2012
    Assignee: Immunogen, Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Methods of treatment using anti-erbb antibody-maytansinoid conjugates
    Patent number: 8093358
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: January 10, 2012
    Assignee: Immunogen, Inc.
    Inventors: Walter Blättler, Ravi V. J. Chari
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
    Patent number: 8088387
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: January 3, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blättler
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 7989598
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 2, 2011
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20100136033
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 3, 2010
    Applicant: IMMUNOGEN, INC.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Patent number: 7585857
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: September 8, 2009
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler
  • Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
    Patent number: 7575748
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Patent number: 7550609
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: June 23, 2009
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Patent number: 7528130
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: May 5, 2009
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Patent number: 7476669
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: January 13, 2009
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20080226659
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: December 3, 2007
    Publication date: September 18, 2008
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE
    Publication number: 20080027130
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Application
    Filed: August 23, 2007
    Publication date: January 31, 2008
    Inventors: Ravi CHARI, Walter BLATTLER
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Patent number: 7276499
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: October 2, 2007
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blattler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Publication number: 20070196332
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Application
    Filed: April 18, 2007
    Publication date: August 23, 2007
    Inventors: Ravi Chari, Walter Blattler
  • Cytotoxic agents comprising taxanes and their therapeutic use
    Publication number: 20070197775
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Application
    Filed: April 18, 2007
    Publication date: August 23, 2007
    Inventors: Ravi Chari, Walter Blattler
  • Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
    Patent number: RE43899
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: January 1, 2013
    Assignee: Immunogen Inc.
    Inventors: Walter A. Blättler, Ravi V. J. Chari